Cell Genesys, Inc. Announces Senior Vice President, Medical Affairs

Strategic Insights

Apr 10, 2005 — 1 min read

Cell Genesys, Inc., a biotechnology company, has announced the appointment of Robert J. Dow as senior vice president, medical affairs. Dow brings over 20 years of biopharmaceutical experience, having previously held senior executive positions at companies such as Biolitec Pharma, Ltd., Quantanova, and Scotia Holdings, plc. He holds a BSc in Medical Science from the University of St. Andrews and an MBChB degree from the University of Dundee in Scotland. Dow will lead the company's global product approval and reimbursement strategy for its lead program, GVAX prostate cancer vaccine, which entered phase III development last year.

Key Takeaways:

Robert J. Dow has joined Cell Genesys, Inc. as senior vice president, medical affairs, bringing over 20 years of biopharmaceutical experience.
Dow was previously chief executive officer of Biolitec Pharma, Ltd. and held senior executive positions at Quantanova and Scotia Holdings, plc.
He holds a BSc in Medical Science from the University of St. Andrews and an MBChB degree from the University of Dundee in Scotland.
Dow will lead the company's global product approval and reimbursement strategy for the GVAX prostate cancer vaccine, which entered phase III development last year.
Matthew J. Pfeffer, vice president and chief financial officer, intends to resign to spend more time with his family but will remain in his position until a successor is appointed.
Pfeffer has contributed significantly to the growth of the company, particularly in fundraising and financial management, during his 9-year tenure.
Stephen A. Sherwin, MD, chairman and chief executive officer, expressed gratitude for Pfeffer's contributions and appreciation for his willingness to serve until a successor is appointed.

Statistics:

20 years of biopharmaceutical experience applied by Robert J. Dow to Cell Genesys, Inc.
9 years of service with Cell Genesys, Inc. by Matthew J. Pfeffer
10 years of service in senior positions at Syntex Corporation by Robert J. Dow

Sources:

Health & Medicine Week editors
NewsRx.com
Copyright 2005, Health & Medicine Week

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients